Stifel analyst Stephen Willey initiated coverage of Compass Therapeutics with a Buy rating and $9 price target. The firm believes the recent presentation at ASCO-GI 2023 of updated results from the Phase 2 trial of the combination of CTX-009 and paclitaxel in second-line BTC increases confidence in a clear, high-probability path to registration via the Phase 2/3 trial that is now recruiting. Regulatory approvals in this "limited/no-option patient population" represents a near-$1B peak sales opportunity worldwide, the firm tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CMPX:
- Compass Therapeutics added to Best Ideas List at Wedbush
- Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
- Compass Therapeutics’ CTX-009 demonstrates efficacy in Phase 2 trial
- Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
- Compass announces first patient dosed in Phase 2 U.S. study of CTX-009